Abraham Morgentaler, MD, FACS, presented “Androgen Society 3rd Annual Meeting Review (Day 1)” for the Grand Rounds in Urology audience in May 2021.
How to cite: Morgentaler, Abraham. “Androgen Society 3rd Annual Meeting Review (Day 1)” May 2021. Accessed Nov 2024. https://dev.grandroundsinurology.com/androgen-society-3rd-annual-meeting-review-day-1/
Androgen Society 3rd Annual Meeting Review (Day 1) – Summary:
Abraham Morgentaler, MD, FACS, Associate Clinical Professor of Urologic Surgery at Harvard University, reviews the first day of the 3rd annual meeting of the Androgen Society, an international organization consisting of healthcare professionals interested in testosterone deficiency and its treatment. Dr. Morgentaler notes that the day began with a presentation on the history of testosterone by Dr. Nieschlag, followed by a presentation by Drs. Ethan D. Grober and Michael S. Irwig on transgender men and the physical impact of testosterone. Dr. Morgentaler then reviews a panel discussion that covered the use of free testosterone, erythrocytosis management, and the role of testosterone therapy and PDE5 inhibitors in men with erectile dysfunction and low testosterone. He goes on to summarize presentations by Drs. E. David Crawford and Omer Raheem which covered the use of androgen deprivation therapy (ADT) in local disease, biochemical failure, and advanced disease, as well as the sexual effects of testosterone. Dr. Crawford presented data showing that there is value in having a testosterone level below 20 nanograms per deciliter, and Dr. Raheem discussed a study that found that different forms of ADT should be used depending on patients’ cardiovascular issues. Dr. Morgentaler concludes by considering new testosterone formulations, including testosterone undecanoate, an oral soft gel, and injectables.
Summaries of days 2 and 3 of this conference will be posted on GRU in the coming weeks. For more on ADT, visit our Next Generation Androgen Deprivation Therapy Learning Center.
ABOUT THE AUTHOR
Abraham Morgentaler, MD, graduated from Harvard College in 1978 and Harvard Medical School in 1982. Dr. Morgentaler completed his residency in 1988 through the Harvard Program in Urology, and then joined the faculty of Beth Israel Deaconess Medical Center and Harvard Medical School. He is currently an Associate Clinical Professor of Surgery (Urology) at Harvard Medical School. In 1999, Dr. Morgentaler founded Men's Health Boston, the first center in the US to focus on sexual, reproductive, and hormonal health for men. Dr. Morgentaler was the recipient of the New Investigator Award in 1994 granted by the American Foundation of Urological Disease. Dr. Morgentaler is an international authority on men’s health and a pioneer in the treatment of testosterone deficiency in men. Dr. Morgentaler’s research is credited with reversing the decades-old belief that testosterone therapy is risky for prostate cancer. Dr. Morgentaler has published over 120 scientific articles on testosterone, prostate cancer, male sexual dysfunction, and male infertility. His work has appeared in The New England Journal of Medicine, The Lancet, The Journal of the American Medical Association, Cancer, and The American Journal of Medicine. He is the author of the book Why Men Fake It: The Totally Unexpected Truth About Men and Sex, which has been widely hailed as a groundbreaking exploration of male sexuality. Dr. Morgentaler’s other books include Testosterone For Life: Recharge Your Vitality, Sex Drive, Muscle Mass, and Overall Health, and The Viagra Myth: The Surprising Impact on Love and Relationships.
